PTPI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 117970 min ago

@ $1.580

Wydano: 13 vas. 2024 @ 20:18

Zwrot: -54.85%

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	373 690
Średni wolumen	789 132
Kapitalizacja rynkowa	4.90M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.00600 (0.85%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Bernstein Bruce	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	54 533	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	49 645	Common Stock
2023-12-21	Walker Wayne Remell	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Arnold Mitchell	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
90.62
Last 73 transactions
Buy: 12 778 148 \| Sell: 66 349

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: -0.65 (moderate negative)

Signal:(40.215) Neutral

Petros Pharmaceuticals, Korelacja

10 Najbardziej pozytywne korelacje
ALZN	0.942
AVO	0.941
AMTI	0.922
TCRT	0.913
LYRA	0.91
FATE	0.908
IMCC	0.908
LQDT	0.906
GH	0.905
BIMI	0.903

10 Najbardziej negatywne korelacje
BNIXU	-0.927
OPNT	-0.924
DVCR	-0.923
LWAY	-0.919
STAY	-0.919
AVEO	-0.911
ITMR	-0.907
CIIG	-0.906
VLYPP	-0.904
GLLI	-0.9

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Petros Pharmaceuticals, Korelacja - Waluta/Towar

-0.29
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.07
( neutral )

Petros Pharmaceuticals, Finanse

Annual	2023
Przychody:	$5.82M
Zysk brutto:	$908 201 (15.60 %)
EPS:	$-3.75

FY	2023
Przychody:	$5.82M
Zysk brutto:	$908 201 (15.60 %)
EPS:	$-3.75

FY	2022
Przychody:	$5.99M
Zysk brutto:	$3.70M (61.79 %)
EPS:	$-13.06

FY	2021
Przychody:	$7.81M
Zysk brutto:	$6.21M (79.52 %)
EPS:	$-1 682.68

Financial Reports:

No articles found.

Petros Pharmaceuticals,

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.